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Tuberculosis/HIV co-infection
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Abstract: Tuberculosis (TB) is the only opportunistic infection,
which is transmissible to the healthy immunocompetent host. HIV
is the most important known risk factor that promotes progression
to active TB in people with Mycobacterium tuberculosis infection.
The lifetime risk of tuberculosis in immunocompetent persons is
5% to 10%, but in HIV positive patients, there is a 5% to 15% annual
risk of developing active TB disease. During the past two decades,
TB has become the major opportunistic infection complicating the
HIV epidemic worldwide, especially in Asia and Africa.
India has one of the world’s highest burdens of both TB (∼2.1
million cases annually) and HIV infection (2.3 million prevalent
cases). While TB occurs in all socioeconomic strata and ethnic
groups, prevalence rates have been clearly linked to poverty. It has
been estimated that undernutrition, HIV, smoking and diabetes are
all strong risk factors for TB.Maternal TB in anHIV-infectedwoman
is a risk factor for transmission of HIV to the infant and is associ-
ated with premature delivery or low-birth weight and with higher
maternal and infant mortality.
Patients with advanced immunodeﬁciency are at high risk for
acquisition of Rifampicin resistance when treated with twice-
weekly or thrice-weekly regimens. This is possibly due to
malabsorption and low blood levels of anti-TB drugs. Cure rates
with standard anti-TB treatment regimens average 86%, but out-
comes in HIV-infected individuals are worse than uninfected
patients. Though most HIV-infected patients respond well to anti-
tuberculosis treatment (ATT) initially, there is a signiﬁcant risk of
developing other opportunistic infections as well as recurrent TB,
leading to increased mortality. Timely initiation of antiretroviral
therapy (ART) has been shown to reduce mortality and improve
long-term outcome of these patients. Several trials have now
shown that early initiation of ART (within the ﬁrst few weeks of
ATT) reduces mortality and improves TB outcomes. The choice of
ART regimen is governed by the drug-drug interactions between
anti-TB and antiretroviral drugs: rifampicin is an inducer of the
cytochrome p450 enzyme system, which metabolizes NNRTI drugs
nevirapine and efavirenz. The metabolism of the latter is less
affected by rifampicin and hence efavirenz is the NNRTI of choice
when combined with ATT.
The 4 “I” policy for addressing co-infection of TB and HIV
includes intensiﬁed case ﬁnding, infection control, isoniazid pre-
ventive chemotherapy and integration of TB and HIV services
within antenatal, PMTCT, family planning and immunization ser-
vices. Since HIV has become a chronic, manageable condition, the
challenge ahead is to provide services to patients in an integrated
manner and strengthen health systems so that long-term care can
be effectively provided. Research priorities include improved and
more sensitive point of care diagnostics for TB, shorter and more
effective TB treatment regimens with minimum drug interactions
with antiretroviral drugs and a better TB vaccine that is safe and
effective in HIV-infected populations.
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Cryptococcal meningitis and beyond -
Management of select opportunistic infections
in Sub-Saharan Africa
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Abstract: In sub-Saharan Africa, despite successful scale-up of
ART programmes, opportunistic infections remain a frequent cause
of morbidity, hospitalization and death. Factors that contributed
to this are delays to HIV diagnosis, late engagement in ART care,
difﬁculties with ART adherence and many patients not remaining
engaged in care. Although tuberculosis is themost frequent HIV co-
infection in the region, other opportunistic infections also result in
considerable morbidity and mortality.
The main focus of this presentation will be cryptococcal menin-
gitis. National surveillance data from South Africa show that
6000-8000 cases of cryptococcosis have been diagnosed annually
over the last decade. Case fatality rates remain extremelyhigh,with
around two-thirds of patients dying or being lost to follow-up in
routine clinical settings and one-third in clinical trial settings. In
terms of management, a randomized controlled trial conducted
in Vietnam demonstrated that the induction antifungal therapy
associated with the best survival was a combination of ampho-
tericin B with ﬂucytosine for 2 weeks. Flucytosine access is limited
in sub-Saharan African countries, but this is being addressed by
advocacy initiatives. Sertraline has anti-cryptococcal activity and
is currently being evaluated as an addition to combination ther-
apy. Over 60% of patients have raised intracranial pressure; this is
managedwith serial therapeutic lumbar punctures. Unlike TB, very
early ART has been shown to increase mortality in patients with
cryptococcal meningitis: in the Cryptococcal Optimal ART Timing
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(COAT) trial those participants who started ART 1-2 weeks after
cryptococcal diagnosis had a 73% higher mortality rate compared
with those started 5-6 weeks after diagnosis. Immune reconstitu-
tion inﬂammatory syndrome (IRIS) is reported in 20% of patients
with cryptococcal meningitis starting ART; management of this
condition will be discussed.
Among all patients with CD4 counts < 100 presenting for HIV
care in sub-Saharan Africa 2-20% are found to have cryptococcal
antigenaemia even though most do not have clinical features of
meningitis at the time. Observational data and ﬁndings of a cluster-
randomised trial suggest that pre-emptive ﬂuconazole for such
antigenaemic patientsmaypreventmeningitis anddeath. The opti-
mal dose and duration of ﬂuconazole for this indication needs to be
deﬁned.
Other important opportunistic disease contributing to HIV-
related mortality in the region (pneumocystis pneumonia,
Karposi’s sarcoma and chronic gastro-enteritis) will be discussed,
but this presentation will not address HIV-associated tuberculosis.
http://dx.doi.org/10.1016/j.ijid.2016.02.044
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Challenges in the management of opportunistic
infections: Focus on Southeast Asia
A. Kamarulzaman
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Abstract: Latepresenters intoHIVcare remaincommon inSouth
East Asia. In an analysis of more than 3700 patients in an Asian
observational cohort, more than 72% were late presenters ie pre-
senting into HIV care for the ﬁrst time with CD4 of < 200 cells/mm3
or with an AIDS deﬁning illness. Consequently physicians in South
East Asia continue to manage patients who present with a myriad
of opportunistic infections including toxoplasmosis, CMV infection,
disseminated fungal infections and tuberculosis. Advanced HIV
infection also leads to an increased risk for immune reconstitution
syndrome which may present as a diagnostic and or therapeutic
challenge in these patients.
Apart from late presentation, substance use disorder and coin-
fections with hepatitis B and C are also relatively common in the
region and can lead to additional challenges in the management
of opportunistic infections and provision of antiretroviral therapy.
Drug-drug interaction and hepatotoxicity are amongst the difﬁcul-
ties that may be encountered in these patients.
A further important consideration when managing patients
with opportunistic infections is the optimal timing for the initiation
of antiretroviral therapy. In recent years several large clinical tri-
als have been performed to address this issue especially in relation
to tuberculosis. These and data from observational studies would
suggest that early initiation of antiretroviral therapy in the setting
of active opportunistic infections confer survival beneﬁts with the
exception of tuberculous meningitis and cryptococcal meningitis.
Despite the advances that havebeenmade in antiretroviral ther-
apy and a global call for early and immediate initiation of treatment
on diagnosis, a large majority of patients continue to present with
late stage diseasewith opportunistic infections. Physicians in South
East Asia and other low and middle income countries need to con-
tinue be equipped with the ability to diagnose and manage these
infections effectively.
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The challenge of opportunistic infections: Focus
on South America
J. Torres
Universidad Central de Venezuela, Caracas,
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Abstract: Some opportunistic diseases are either exclusive or
more commonly observed in South American AIDS patients than
in those from different parts of the world. Interactions between
HIV and endemic parasitic and other locally prevalent pathogens
occur frequently in South America. However, knowledge about the
impact of these interactions has been accumulating only recently.
HIV infection may alter the natural history of tropical diseases
in different ways. Diagnosis and treatment may be altered and an
increased pathogen burdenmay augmentmorbidity andmortality.
The impact that tropical diseaseshaveon thecourseofHIV infection
may also be deleterious. Many intercurrent infections increase the
HIV viral load enhancing the progression of HIV disease and the
risk of transmission of HIV to non-infected individuals. Similarly,
chronic immunomodulation by pathogens, such as helminths and
protozoa, may considerably accelerate the natural history of HIV
infection.
Characteristics of coinfection in the region with HIV and some
emblematic endemic pathologies, such as paracoccidioidomycosis,
histoplasmosis, Chagas’ disease, visceral leishmaniasis, strongy-
loidiasis and HTLV1, as well as some unique challenges posed by
them, are reviewed in detail.
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Mers-CoV: From camels to humans
Z. Memish
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Abstract: The Middle East respiratory syndrome coronavirus
(MERS-CoV) is a novel enzootic beta coronavirus that was ﬁrst
described in September 2012. The clinical spectrum of MERS-CoV
infection in humans ranges from an asymptomatic or mild respira-
tory illness to severe pneumonia and multi-organ failure; overall
